Spero Therapeutics, Inc. (NASDAQ:SPRO) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Spero Therapeutics has received a consensus rating of "Hold" from five brokerages, with one analyst rating it a sell, two as hold, and two as buy.
• The stock's average 12-month price objective among analysts is $5.00, while shares recently traded at $2.05.
• Recent institutional investments include significant increases in holdings by Anson Funds Management and Mackenzie Financial Corp, contributing to 25.60% of the stock being owned by institutional investors.

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) has been given a consensus recommendation of "Hold" by the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $5.00.

SPRO has been the subject of a number of research reports. Wall Street Zen raised shares of Spero Therapeutics to a "hold" rating in a research note on Saturday, June 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of Spero Therapeutics in a research note on Saturday, September 27th.

Institutional Investors Weigh In On Spero Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Anson Funds Management LP raised its holdings in Spero Therapeutics by 98.9% during the 1st quarter. Anson Funds Management LP now owns 7,638,818 shares of the company's stock valued at $5,500,000 after buying an additional 3,798,932 shares during the last quarter. Stonepine Capital Management LLC bought a new stake in Spero Therapeutics during the 2nd quarter valued at $455,000. Mackenzie Financial Corp raised its holdings in Spero Therapeutics by 487.9% during the 4th quarter. Mackenzie Financial Corp now owns 187,559 shares of the company's stock valued at $193,000 after buying an additional 155,656 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Spero Therapeutics during the 4th quarter valued at $57,000. Finally, Jane Street Group LLC bought a new stake in Spero Therapeutics during the 4th quarter valued at $54,000. 25.60% of the stock is currently owned by institutional investors.

Spero Therapeutics Trading Up 1.0%

Shares of SPRO traded up $0.02 during trading hours on Friday, reaching $2.05. 379,982 shares of the stock traded hands, compared to its average volume of 1,657,903. The stock has a fifty day simple moving average of $2.03 and a 200 day simple moving average of $1.74. Spero Therapeutics has a 52 week low of $0.51 and a 52 week high of $3.22. The company has a market cap of $115.37 million, a price-to-earnings ratio of -2.09 and a beta of 1.47.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.35. The firm had revenue of $14.19 million during the quarter, compared to the consensus estimate of $11.00 million. Spero Therapeutics had a negative net margin of 110.35% and a negative return on equity of 120.27%. Analysts predict that Spero Therapeutics will post -1.2 earnings per share for the current fiscal year.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.